|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||





,1
* Department of Microbiology, National Taiwan University, Taipei, Taiwan; and
Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
1 Correspondence: Institute of Biomedical Sciences, Academia Sinica, 128, Sec. 2, Academia Rd., Taipei, Taiwan 115, ROC. E-mail: konan{at}ibms.sinica.edu.tw
Toll-like receptors (TLRs) play important roles in the immune responses against invading microorganisms. Development of TLR antagonists is recognized as a promising direction in suppressing the associated inflammatory reactions of the TLRs. Aptamers are single-stranded RNA or DNA molecules isolated through an in vitro selection process. Using a novel molecular evolution strategy that combines immunoprecipitation (IP) with systematic evolution of ligands by exponential enrichment (SELEX), we developed an IP-SELEX selection method to facilitate the screening of high-affinity aptamers for the Toll-like receptor 2 (TLR2). Also, human TLR2 functional aptamers were identified and characterized using NF-
B reporter assays. Among the functional aptamers, the most effective, AP177, with a dissociation constant of 73 pM, was characterized with TLR2-expressing cells challenged with bacterial cells and purified ligands. The aptamer could effectively antagonize TLR2, significantly inhibit NF-
B activity, and suppress the secretion of the cytokines by >80%. In addition, the precise region within the functional aptamer that specifically bound TLR2 was resolved using aptamer microarray analysis. The results of functional assays showed that AP177 acted as a TLR2 antagonist and may hold therapeutic potential in the treatment of diseases related to dysregulated TLR2 immune responses.—Chang, Y.-C., Kao, W.-C., Wang, W.-Y., Wang, W.-Y., Yang, R.-B., Peck, K. Identification and characterization of oligonucleotides that inhibit Toll-like receptor 2-associated immune responses.
Key Words: aptamer microarray microbial infection IP-SELEX
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |